Tocilizumab for treatment of mechanically ventilated patients with COVID-19

Mostrar otras versiones (1)

BACKGROUND: Severe COVID-19 can manifest in rapid decompensation and respiratory failure with elevated inflammatory markers. This presentation is consistent with cytokine release syndrome in chimeric antigen receptor T cell therapy, for which IL-6 blockade is approved treatment. METHODS: We assessed...

Descripción completa

Detalles Bibliográficos
Autores principales: Somers, Emily C, Eschenauer, Gregory A, Troost, Jonathan P, Golob, Jonathan L, Gandhi, Tejal N, Wang, Lu, Zhou, Nina, Petty, Lindsay A, Baang, Ji Hoon, Dillman, Nicholas O, Frame, David, Gregg, Kevin S, Kaul, Dan R, Nagel, Jerod, Patel, Twisha S, Zhou, Shiwei, Lauring, Adam S, Hanauer, David A, Martin, Emily, Sharma, Pratima, Fung, Christopher M, Pogue, Jason M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7302290/
https://www.ncbi.nlm.nih.gov/pubmed/32577684
http://dx.doi.org/10.1101/2020.05.29.20117358

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7302290/
https://www.ncbi.nlm.nih.gov/pubmed/32577684
http://dx.doi.org/10.1101/2020.05.29.20117358

Ejemplares similares